Kailera Therapeutics is trading at $12.18, down 5.29%, with biotech-sector weakness a possible contributing factor. - Biotech ETF XBI is down 2.39%; broader major indexes are higher, so the decline does not appear aligned with the broader-market rebound. - No company-specific announcement explaining the November 2, 2026 decline surfaced in available search results. The latest company news found was from October, and no clear company-specific catalyst is confirmed.